SK Bioscience, which developed Korea's No. 1 COVID-19 vaccine, aims to shorten the development period of the mRNA vaccine to 100 days and create innovative technology that can be supplied to the world within six months.
#1
Choi Chang-won, vice chairman of SK Discovery's CEO, gave a keynote speech at the "2022 Global Bio Conference" held at Grand InterContinental Parnas in Seoul on the 5th on the importance of global cooperation to respond to the next pandemic. SK Discovery is a holding company of SK Bioscience. SK Bioscience obtained the item license for the COVID-19 vaccine SKYCovione from the Ministry of Food and Drug Safety for the first time in Korea on June 29, and has been vaccinated in earnest since